Prineeta Kulkarni is transforming how microbiome science translates into life-changing therapeutics as head of strategy and corporate development at Vedanta Biosciences. Leading the strategic vision for a pipeline spanning gastroenterology, immunology and infectious diseases, she architects partnerships and financing strategies that have secured over $110 million in capital, positioning Vedanta as a leader in microbiome-based drug development.
With a Master of Business Administration from Harvard Business School and Master of Science in biotechnology from Savitribai Phule Pune University, Kulkarni combines scientific depth with exceptional business acumen. Her early career at Regeneron and Cipla provided foundational expertise in market access, business development and corporate strategy across global markets.
At Vedanta, Kulkarni single-handedly directs all pharmaceutical partnering activities, designing and executing business development strategies for the company’s late-stage clinical candidates. She leads investor relations, board communications and strategic planning initiatives that directly impact the company’s ability to advance breakthrough therapies for underserved patient populations.
Kulkarni’s leadership extends beyond traditional corporate development. She drives cross-functional collaboration across clinical, commercial and finance teams while maintaining focus on health equity and patient access. Executive leadership consistently recognizes her ability to surface critical strategic questions, deliver high-impact analyses and demonstrate the executive presence characteristic of future industry leaders.
Through her work advancing novel microbiome therapeutics, Kulkarni exemplifies the next generation of biotech leaders who seamlessly blend scientific innovation with strategic excellence to improve patient outcomes globally.